Low-Dose Naltrexone (LDN)

Naltrexone (off-label low dose)

Low-Dose Naltrexone (LDN) uses a fraction of the standard naltrexone dose (1.5–4.5 mg) to produce immunomodulatory effects — most studied in fibromyalgia, with growing interest in Crohn's and other autoimmune conditions. Cheap, generally well-tolerated, and evidence is moderate-but-real.

Opioid antagonist (paradoxical low-dose immunomodulator)Prescription requiredEvidence C
⚠ Not medical advice.Not medical advice. This page is educational. Discuss with your physician before starting, changing, or stopping any medication.

Why it matters

LDN sits in an unusual evidence space: cheap, generally safe, mechanistically interesting, and supported by small but consistent randomized trial data — yet no major medical society endorses it as standard care for any condition. The strongest data is in fibromyalgia, where Jarred Younger's lab at Stanford and later UAB conducted two small RCTs (2013, 2014) showing meaningful pain reduction in roughly a third to half of patients. The 2018 Patten review summarized the broader off-label landscape: signal for Crohn's disease (Smith trials), multiple sclerosis (quality-of-life endpoints), and an open question in Hashimoto's, ME/CFS, and chronic regional pain. Bruun-Plesner's 2020 systematic review concluded the fibromyalgia data is suggestive but underpowered. The mechanism — transient opioid receptor blockade plus TLR4-mediated microglial modulation — is plausible and preclinically supported. The clinical reality: a meaningful subset of patients with autoimmune or chronic pain conditions respond robustly; many do not; few are clearly harmed at low doses. For appropriate conditions, LDN is a reasonable empirical trial. Evidence grade: C — better than anecdote, weaker than guideline-grade, with mechanism and trial signal pulling in the right direction.

Uses

Label uses (approved)
  • Alcohol use disorder (50 mg)
  • Opioid use disorder (50 mg)

Dosing

Label dose
50 mg daily (standard dose, FDA-approved indications)
Off-label / biohacker dose
1.5–4.5 mg nightly (typical LDN protocol); some clinicians titrate from 0.5 mg upward over weeks
Titration: Start 1.5 mg nightly for one week, increase to 3 mg for one week, then 4.5 mg. If vivid dreams or sleep disruption persist, drop back. Some patients respond to as little as 2 mg.
When to take: Nightly, before bed (some protocols use morning if sleep is disrupted)

Side effects & warnings

Common
  • Vivid dreams
  • Sleep disruption (especially first 1–2 weeks)
  • Mild headache
  • Nausea
  • Anxiety (uncommon)
Uncommon but serious
  • Transaminase elevation (rare at low doses; clinically significant at high doses)
  • Mood changes
Serious warnings
LDN at 1.5–4.5 mg is generally very well tolerated — but it is an opioid antagonist. Anyone taking opioid analgesics (including tramadol, codeine, some cough syrups) will get partial blockade. LDN must not be combined with opioid pain management without explicit prescriber coordination. Compounding pharmacy product varies in quality.

Biomarkers affected

hscrp
variable
Small studies suggest modest reductions in inflammatory markers in responders; data is limited and inconsistent.
Evidence: weak
wbc
variable
Immunomodulatory mechanism (TLR4 / microglial) may shift WBC subsets in autoimmune patients; clinical bloodwork changes are not well-characterized.
Evidence: weak

Monitoring

Liver function tests (baseline and annual). Symptom-based follow-up for autoimmune indications.

The honest risk picture

## Realistic risks of low-dose naltrexone **It is a real opioid antagonist.** Even at low doses, LDN blocks opioid receptors for several hours. Combining with opioid painkillers (oxycodone, hydrocodone, tramadol, codeine, even some cough syrups) reduces or eliminates their analgesic effect. Anyone needing surgery or post-operative opioids must coordinate with the prescriber — stop LDN well in advance. **Sleep disruption and vivid dreams:** The most common early side effect. Usually resolves in 1–2 weeks. Some clinicians switch to morning dosing if sleep impact persists. **Compounding quality varies:** No FDA-approved low-dose finished product exists. All LDN comes from compounding pharmacies. Choose one with documented quality controls. **The evidence is suggestive, not definitive:** Most trials are small (n<50). Larger phase III studies are lacking. LDN is not standard of care for any condition. Major rheumatology and gastroenterology guidelines do not recommend it. **Non-responders exist:** Across LDN trials, response rates for fibromyalgia and Crohn's are typically 30–50%. Many patients try LDN and feel nothing. **Liver:** Transaminase elevation is well-documented at standard doses (50 mg) but uncommon at LDN doses. Baseline and periodic LFTs are reasonable. **Mood:** Rare cases of worsening anxiety or mood reported — discontinuation reverses. **Empirical trial framework:** LDN is best approached as a 2–3 month empirical trial with clear objective endpoints (pain scores, symptom diaries, biomarkers). If no benefit, stop. The downside is small; the upside, when it works, is meaningful.

Practical context

Cost (US, retail)
$40/mo
Legality
Naltrexone is a prescription medication in the US. Low-dose formulations are compounded — no FDA-approved finished LDN product exists. Insurance coverage is inconsistent.
Interactions
true

FAQ

Does LDN actually work for fibromyalgia?+
In several small RCTs (Younger 2013, 2014), a meaningful subset of fibromyalgia patients experienced reduced pain — typically 30%+ improvement in around 30–50% of responders. It is not a universal treatment, but for responders the effect can be substantial. Larger phase III trials are still lacking.
Why does LDN not interfere with opioid receptors all day?+
The hypothesis is that brief receptor blockade (a few hours, depending on dose and timing) triggers compensatory upregulation of endogenous opioids and modulates microglial TLR4 signaling. The mechanism is plausible and supported by preclinical work, but not fully nailed down.
Can I take LDN with painkillers?+
Not without coordination. LDN blocks opioid receptors — that means opioid analgesics (oxycodone, hydrocodone, tramadol, codeine) will work less well or not at all while LDN is active. Stop LDN well before any anticipated surgery or planned opioid use.
Where do I get LDN?+
From a compounding pharmacy with a prescription. No FDA-approved low-dose product exists. Pharmacy quality matters — use one with documented sterility and consistency.
References (5)+
  1. Low-Dose Naltrexone for the Treatment of Fibromyalgia — RCT (Younger et al., Arthritis Rheum 2013).
  2. The Use of Low-Dose Naltrexone (LDN) as a Novel Anti-Inflammatory Treatment for Chronic Pain (Younger et al., Clin Rheumatol 2014).
  3. Low-Dose Naltrexone in the Treatment of Crohn's Disease (Smith et al., Am J Gastroenterol 2007 / Dig Dis Sci 2011).
  4. The Promise of Low Dose Naltrexone Therapy: Potential Benefits in Cancer, Autoimmune, Neurological and Infectious Disorders (Patten et al., 2018).
  5. Low-Dose Naltrexone for the Treatment of Fibromyalgia — Systematic Review (Bruun-Plesner et al., 2020).
The prime report

Weekly performance intelligence.

New studies, protocols, and optimization frameworks delivered every Monday. No fluff, no motivation quotes — only what moves the needle.

No spam. Unsubscribe anytime.